A prospective phase II study of multimodal prophylactic treatment for afatinib-induced adverse events in advanced non-small cell lung cancer (Niigata Lung Cancer Treatment Group 1401)

BACKGROUND: Afatinib has shown clinical benefits in patients with non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutations. Many patients treated with afatinib experience skin or gastrointestinal toxicity. However, an effective management strategy has not been e...

Descripción completa

Detalles Bibliográficos
Autores principales: Okajima, Masaaki, Miura, Satoru, Watanabe, Satoshi, Tanaka, Hiroshi, Ito, Kazuhiko, Ishida, Takashi, Makino, Masato, Iwashima, Akira, Matsumoto, Naoya, Sato, Kazuhiro, Ichikawa, Kosuke, Abe, Tetsuya, Yoshizawa, Hirohisa, Kikuchi, Toshiaki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7867768/
https://www.ncbi.nlm.nih.gov/pubmed/33569309
http://dx.doi.org/10.21037/tlcr-20-649

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7867768/
https://www.ncbi.nlm.nih.gov/pubmed/33569309
http://dx.doi.org/10.21037/tlcr-20-649

Ejemplares similares